BioAge Labs

BIOA

ATLANTA, GA – – (Globe Newswire – December 11, 2024) – – Holzer & Holzer, LLC is investigating whether BioAge Labs, Inc. (“BioAge” or the “Company”) (NASDAQ: BIOA) complied with federal securities laws. On December 6, 2024, BioAge announced the discontinuation of the Strides Phase 2 study of its investigational drug candidate azelaprag due to safety concerns “after liver transaminitis without clinically significant symptoms was observed in some subjects receiving azelaprag.”  Following this news, the price of the Company’s stock dropped.

If you purchased BioAge stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at cholzer@holzerlaw.com or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com/case/bioage-labs/ to discuss your legal rights.

Registration Deadline

Lead Plaintiff Deadline Has Passed

Submit Your Information
Submit Your Form

Submit Your Information

Name(Required)
Address
Shares Purchased(Required)
Date of Shares Purchased
Number of Shares Acquired
Acquisition Price Per Share
 
Shares Sold
Date of Shares Sold
Number of Shares Sold
Selling Price Per Share
 
By clicking on the button below, I am requesting Holzer & Holzer, LLC send me documents necessary to retain the firm.